Impact of targeting insulin-like growth factor signaling in head and neck cancers

Kirsten H. Limesand, Alejandro Martinez Chibly, Andrew Fribley

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


The IGF system has been shown to have either negative or negligible impact on clinical outcomes of tumor development depending on specific tumor sites or stages. This review focuses on the clinical impact of IGF signaling in head and neck cancer, the effects of IGF targeted therapies, and the multi-dimensional role of IRS 1/2 signaling as a potential mechanism in resistance to targeted therapies. Similar to other tumor sites, both negative and positive correlations between levels of IGF-1/IGF-1-R and clinical outcomes in head and neck cancer have been reported. In addition, utilization of IGF targeted therapies has not demonstrated significant clinical benefit; therefore the prognostic impact of the IGF system on head and neck cancer remains uncertain.

Original languageEnglish (US)
Pages (from-to)135-140
Number of pages6
JournalGrowth Hormone and IGF Research
Issue number5
StatePublished - Oct 2013


  • Clinical outcomes
  • Head and neck cancer
  • IGF inhibition

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Impact of targeting insulin-like growth factor signaling in head and neck cancers'. Together they form a unique fingerprint.

Cite this